Last reviewed · How we verify
ADRABETADEX
ADRABETADEX is being tested in clinical trials for cold sores, a rare genetic disorder, and stroke.
ADRABETADEX is an investigational agent evaluated in Phase 2 trials for recurrent herpes labialis, Niemann-Pick Type C disease, and acute ischemic stroke, though its exact mechanism class is not specified in the source.
At a glance
| Generic name | ADRABETADEX |
|---|---|
| Modality | Oligosaccharide |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
ADRABETADEX is currently being studied in several clinical trials for different conditions. It is being tested for recurrent cold sores, a genetic disorder called Niemann-Pick Type C disease, and for treating stroke. The drug is still in the early stages of research, so its exact effects and benefits are not yet fully understood.
Approved indications
Common side effects
Key clinical trials
- Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C (Phase 1)
- A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IIb Clinical Trial of Androtriol Injection for the Treatment of Acute Ischemic Stroke (Phase 2)
- A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Choleste (Phase 1)
- Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin (Phase 3)
- Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC) (Phase 3)
- Safety, Tolerability and Preliminary Pharmacokinetics of Single Rising Doses of 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg, 125 mg and 150 mg BIIB 722 CL (Calculated (Phase 1)
- A Phase 2B/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301 (Phase 2)
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers. (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADRABETADEX CI brief — competitive landscape report
- ADRABETADEX updates RSS · CI watch RSS
- portfolio CI